Humanity’s List

Section

Biology

Genomes, cells, brains, and the tools that read and write them.

Daily at 05:45 UTC

Edition No. 31
Updated UTC

Stronger verdicts first · Score orders stories within each verdict

Europe PMC

Verdict: Major

Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China

Izalontamab brengitecan (iza-bren) is a first-in-class bispecific antibody-drug conjugate targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3) and has shown…

By Hong, Zhou, Hou +43Lancet (London, England)

Score█████░░░░░4.8

Top stories

  1. 1. Phenologs at knowledge-graph scale: a mouse-to-slime-mold catalog of candidate genes for thousands of human diseases

    Model organisms carry decades of systematic gene-phenotype annotation, but connecting those annotations to human disease is rarely straightforward.

    Verdict: Notable█████░░░░░4.8

  2. 2. Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China

    Ruzaltatug rezetecan is a novel HER3-directed antibody-drug conjugate that has shown promising antitumour activity and manageable safety in pretreated EGFR-.mutated non-small-cell lung cancer (NSCLC) in a…

    Verdict: Major█████░░░░░4.5

More top stories

No.03 to No.06

  1. bioRxivby Pythia Labs Team, Aglietti, Ansari +15

    Design of full-length agonist and antagonist antibodies for hard targets

    Therapeutic antibodies have transformed modern medicine, yet conventional discovery relies on lengthy experimental workflows, offers limited control over how antibodies engage their ....

    No.03Verdict: NotableScore████░░░░░░4.4

Briefs

8 more from the desk